Sarfaraz K. Niazi, PhD, summarizes some of the lessons that the entire biosimilar industry can take away from 2022, including what new legislation and policy changes could mean for future biosimilar development.
A year-end is a way to define a time boundary that allows me to summarize a few events of relevance to biosimilars and offer brief perspective comments on how to benefit from the experience of the year 2022, both for developers and regulatory agencies.
. Jumper J, Evans R, Pritzel A, et al. Highly accurate protein structure prediction with AlphaFold. Nature. 2021;596:583-589. doi:1038/s41586-021-03819-2
. Niazi SK. Molecular Biosimilarity-An AI-Driven Paradigm Shift. Int J Mol Sci. 2022;23(18):10690. doi:10.3390/ijms231810690.